Scarica l'app Stockscreener
2.11
7.65%
0.15
Precedente Chiudi:
$1.96
Aprire:
$1.97
Volume 24 ore:
624.46K
Relative Volume:
1.00
Capitalizzazione di mercato:
$203.64M
Reddito:
$447.48M
Utile/perdita netta:
$-14.55M
Rapporto P/E:
-21.10
EPS:
-0.1
Flusso di cassa netto:
$7.61M
1 W Prestazione:
+15.30%
1M Prestazione:
+20.57%
6M Prestazione:
+39.74%
1 anno Prestazione:
-21.85%
Intervallo 1D:
$1.9561
$2.12
Intervallo di 1 settimana:
$1.81
$2.12
Portata 52W:
$1.40
$3.05
Accuray Inc Stock (ARAY) Company Profile
Nome
Accuray Inc
Settore
Industria
Telefono
608-824-2800
Indirizzo
1240 DEMING WAY, MADISON, CA
Confronta ARAY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARAY
Accuray Inc
|
2.11 | 203.64M | 447.48M | -14.55M | 7.61M | -0.10 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Accuray Inc Stock (ARAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-13 | Iniziato | ROTH MKM | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Loop Capital | Buy |
| 2020-01-21 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-11-01 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-12-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-11-30 | Iniziato | Lake Street | Buy |
| 2016-12-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-22 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2015-11-12 | Iniziato | Citigroup | Sell |
| 2015-05-01 | Reiterato | Dougherty & Company | Buy |
| 2015-01-12 | Iniziato | Northland Capital | Outperform |
| 2014-01-31 | Reiterato | Dougherty & Company | Buy |
| 2014-01-29 | Reiterato | Brean Capital | Buy |
| 2013-11-11 | Reiterato | Dougherty & Company | Buy |
| 2013-08-29 | Reiterato | Dougherty & Company | Buy |
| 2011-09-20 | Reiterato | Ticonderoga | Buy |
| 2010-02-08 | Aggiornamento | Jefferies & Co | Hold → Buy |
| 2009-12-09 | Aggiornamento | UBS | Sell → Neutral |
| 2009-03-09 | Downgrade | Soleil | Buy → Hold |
| 2009-01-30 | Aggiornamento | Piper Jaffray | Neutral → Buy |
| 2008-12-22 | Reiterato | Jefferies & Co | Hold |
| 2008-08-20 | Reiterato | Jefferies & Co | Hold |
Mostra tutto
Accuray Inc Borsa (ARAY) Ultime notizie
Accuray (ARAY) Stock Surges Over 5% Amid Market Activity - GuruFocus.com
Accuray Incorporated announces inducement award - Medical Buyer
Accuray Grants 150,000 RSU Equity Award to New VP Controller Mike Murphy | ARAY Stock News - StockTitan
Asia-Pacific Radiation Oncology Market Analysis Report 2025-2030External Beam Radiation Therapy (EBRT) Dominated the Market with a Revenue Share of 35.9% in 2024 - Yahoo Finance
Accuray Stockholders Approve Plans and Appoint New Officer - TipRanks
Heidelberg University Hospital in Germany Invests in Fourth Accu - GuruFocus.com
FY2026 Earnings Forecast for Accuray Issued By Roth Capital - MarketBeat
Accuray Incorporated (NASDAQ:ARAY) Shares Bought by Foundry Partners LLC - MarketBeat
Roth Capital Brokers Reduce Earnings Estimates for Accuray - MarketBeat
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates - MSN
Medical Linear Accelerator Market to Boost Revenue Potential, - openPR
Royce & Associates LP Has $3.39 Million Stake in Accuray Incorporated (NASDAQ:ARAY) - MarketBeat
Non Melanoma Skin Cancer Market Expected To Reach $24.3 Billion - openPR
Accuray (NASDAQ:ARAY) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Bridging Gaps and Making Precision Oncology Accessible Across India with Accuray - Elets
Accuray (NASDAQ:ARAY) Stock Rating Upgraded by StockNews.com - Defense World
Oncology Information Systems Market May See a Big Move| Accuray, Varian Medical Systems, DOSIsoft, ViewRay - openPR
Accuray Incorporated (NASDAQ:ARAY) Q1 2025 Earnings Call Transcript - Insider Monkey
Radiation Therapy Equipment Market Dynamics and Strategies - openPR
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks - Yahoo Finance
Accuray Inc (ARAY) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus.com
Accuray Inc (ARAY) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
Accuray Inc (ARAY) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Accuray Incorporated Reports Strong Start to Fiscal 2025 - TipRanks
Accuray: Fiscal Q1 Earnings Snapshot - San Francisco Chronicle
Accuray Inc (ARAY) Q1 FY2025 Earnings: Revenue Surpasses Estimat - GuruFocus.com
Accuray Inc. Optimistic Despite Revenue Decline - TipRanks
Accuray earnings beat by $0.01, revenue topped estimates - Investing.com UK
Accuray Q1 Earnings Miss: Revenue Slips to $101.5M, Net Loss Widens Amid Product Sales Drop | ARAY Stock News - StockTitan
Accuray (NASDAQ:ARAY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Brain Cancer Treatment Industry Set to Flourish Key Regions - openPR
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024 - StockTitan
Accuray Appoints Michael Murphy as VP Corporate Controller - TipRanks
Accuray Appoints Michael Murphy as VP, Corporate Controller - StockTitan
Comparing enVVeno Medical (NASDAQ:NVNO) and Accuray (NASDAQ:ARAY) - Defense World
Here's Why You Should Retain Accuray Stock in Your Portfolio Now - MSN
New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer - PR Newswire
Philippines Radiotherapy Market to See Booming Growth - openPR
Financial Metrics Unveiled: Accuray Inc (ARAY)’s Key Ratios in the Spotlight - The Dwinnex
Lung Cancer Surgery Market: Detailed Analysis Of Growth Factors - openPR
Accuray CEO Suzanne Winter resumes role after leave By Investing.com - Investing.com Canada
Accuray CEO Returns from Medical Leave - MarketWatch
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence - PR Newswire
Orthopedic Surgical Robot Market is Projected to Reach a Valuation of US$ 8.34 Billion at a CAGR of 13.5% by 2034 | Fact.MR Report - GlobeNewswire Inc.
Accuray Welcomes Back CEO Suzanne Winter for Growth - TipRanks
Radiotherapy Device Market is Likely to Upsurge at USD 25.16 Bn- Varian Medical Systems, Elekta AB, Accuray, Inc., C.R. Bard, Inc., IBA – IndiaPolitics.com - IndiaPolitics.com
Here's Why You Should Retain Accuray (ARAY) Stock for Now - MSN
Radiotherapy Device Market is Likely to Upsurge at USD 25.16 Bn- Varian Medical Systems, Elekta AB, Accuray, Inc., C.R. Bard, Inc., IBA – KnowCasino - KnowCasino
Dimensional Fund Advisors LP Cuts Stock Position in Accuray Incorporated (NASDAQ:ARAY) - Defense World
Dimensional Fund Advisors LP Has $2.46 Million Holdings in Accuray Incorporated (NASDAQ:ARAY) - MarketBeat
Accuray Inc Azioni (ARAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Accuray Inc Azioni (ARAY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chalke Sandeep | SVP, Chief Commercial Officer |
Dec 01 '23 |
Sale |
1.70 |
26,799 |
45,612 |
531,341 |
| Pervaiz Ali | SVP Chief Financial Officer |
Jun 04 '24 |
Sale |
1.70 |
2,701 |
4,597 |
402,542 |
| WHITTERS JOSEPH E | Director |
May 29 '24 |
Buy |
1.58 |
50,000 |
79,000 |
561,053 |
| WHITTERS JOSEPH E | Director |
May 28 '24 |
Buy |
1.54 |
50,000 |
77,045 |
511,053 |
| Hoge Michael | Senior VP Global Operations |
Mar 01 '24 |
Sale |
2.59 |
11,991 |
31,057 |
390,208 |
| Pervaiz Ali | SVP Chief Financial Officer |
Jan 03 '24 |
Sale |
2.74 |
2,116 |
5,800 |
402,743 |
| Corradetti GIna | VP, CAO and Controller |
Jan 03 '24 |
Sale |
2.74 |
14,129 |
38,729 |
196,138 |
| Spine Patrick | SVP, Chief Admin Officer |
Dec 01 '23 |
Sale |
2.47 |
14,832 |
36,653 |
219,484 |
| Winter Suzanne C | President |
Dec 01 '23 |
Sale |
2.47 |
65,390 |
161,624 |
1,369,811 |
| Pervaiz Ali | SVP Chief Financial Officer |
Dec 01 '23 |
Sale |
2.47 |
13,463 |
33,271 |
404,859 |
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):